Peptide ScheduleWeight Loss Peptides
GLP-1 agonists, dual and triple agonists for appetite suppression and metabolic improvement.
Weight loss peptides work by targeting your appetite and metabolism at the hormonal level. Most of them mimic GLP-1, a gut hormone that tells your brain you're full. Some also target GIP or glucagon receptors for stronger effects.
Semaglutide (the active ingredient in Ozempic and Wegovy) is the most studied option here. It's FDA-approved and backed by large clinical trials showing 15-17% body weight loss. Tirzepatide hits two receptors instead of one and may produce even greater results. Retatrutide is the newest — a triple agonist still in Phase 2 trials.
If you're comparing options, the main differences come down to dosing frequency, side effect profile, and how much clinical data exists. All of the GLP-1 peptides below are injected subcutaneously once per week. Our dosage calculators will show you exactly how many units to draw for your vial.
Quick Comparison
| Peptide | Route | Frequency | Half-Life | Status | Grade |
|---|---|---|---|---|---|
| AOD-9604 | SubQ | Daily | ~2 hours | Phase 2 | A |
| Dulaglutide (Trulicity) | SubQ | Weekly | ~5 days | FDA Approved | A |
| Exenatide (Byetta / Bydureon) | SubQ | 2x Daily | ~2.4 hours | FDA Approved | A |
| Liraglutide | SubQ | Daily | ~13 hours | FDA Approved | A |
| Lixisenatide | SubQ | Daily | ~3 hours | FDA Approved | A |
| Tirzepatide | SubQ | Weekly | ~5 days | FDA Approved | A |
| Cagrilintide | SubQ | Weekly | ~7 days | Phase 3 | B |
| CagriSema | SubQ | Weekly | ~7 days | Phase 3 | B |
| Lipo-C | SubQ | 2x/week | Variable | Research | B |
| Orforglipron | Oral | Daily | ~29-68 hours | FDA Approved | B |
| Pramlintide (Symlin) | SubQ | 3x Daily | ~48 minutes | FDA Approved | B |
| Semaglutide | SubQ | Weekly | ~7 days | FDA Approved | B |
| Setmelanotide | SubQ | Daily | ~11 hours | FDA Approved | B |
| Survodutide | SubQ | Weekly | ~6 days | Phase 3 | B |
| 5-Amino-1MQ | Oral | Daily | ~4-6 hours | Research | C |
| Danuglipron | Oral | 2x Daily | ~6-8 hours | Research | C |
| Mazdutide | SubQ | Weekly | ~6-7 days | Phase 3 | C |
| Pemvidutide (ALT-801) | SubQ | Weekly | ~4-6 days | Phase 2 | C |
| Retatrutide | SubQ | Weekly | ~6 days | Phase 2 | C |
| Tesofensine | Oral | Daily | ~9 days | Phase 3 | C |
| Adipotide (FTPP) | SubQ | Daily | ~2-4 hours | Research | D |
All Weight Loss Peptides(21)
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) specifically designed for fat metabolism.
Cagrilintide
Cagrilintide is a long-acting amylin receptor agonist that works through a completely different pathway than GLP-1 dr...
Mazdutide
Mazdutide is a dual-agonist peptide that activates both GLP-1 and glucagon receptors.
Retatrutide
Retatrutide is the first triple-agonist peptide, targeting GLP-1, GIP, and glucagon receptors simultaneously — earnin...
Semaglutide
Semaglutide is a GLP-1 receptor agonist — the same active ingredient in Ozempic and Wegovy.
Survodutide
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist, sold as Mounjaro (diabetes) and Zepbound (obesity).
Liraglutide
Liraglutide is a GLP-1 receptor agonist that's been on the market longer than most people realize — FDA-approved as V...
Orforglipron
Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist — and that distinction matters.
Setmelanotide
Setmelanotide is the first and only FDA-approved treatment targeting the melanocortin-4 receptor (MC4R) pathway for p...
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor originally developed for Alzheimer's and Parkinson's disease, wh...
Lipo-C
Lipo-C is a compounded lipotropic injection blend used in weight management clinics to support fat metabolism.
5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a...
Adipotide (FTPP)
Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-TP01, is a synthetic peptidomimetic d...
Dulaglutide (Trulicity)
Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatm...
Pramlintide (Symlin)
Pramlintide (brand name Symlin) is an FDA-approved synthetic analog of human amylin, a 37-amino acid hormone co-secre...
Exenatide (Byetta / Bydureon)
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally discovered in the saliva of the Gil...
Lixisenatide
Lixisenatide is a 44-amino-acid synthetic peptide derived from exendin-4, a compound originally isolated from the sal...
CagriSema
CagriSema is a first-in-class, fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (...
Pemvidutide (ALT-801)
Pemvidutide (ALT-801) is a dual GLP-1 and glucagon receptor agonist developed by Altimmune for obesity and MASH (meta...
Danuglipron
Danuglipron (PF-06882961) was Pfizer's attempt to enter the GLP-1 weight loss market with an oral small-molecule drug...